



EVIDENCE-BASED
PRACTICES

KIT

Knowledge Informing Transformation

The Evidence

MedTEAM



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Mental Health Services
www.samhsa.gov



The Evidence

MedTEAM

Acknowledgments

This document was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by the New Hampshire-Dartmouth Psychiatric Research Center under contract number 280-00-8049 and Westat under contract number 270-03-6005, with SAMHSA, U.S. Department of Health and Human Services (HHS). Pamela Fischer, Ph.D., and Crystal Blyler, Ph.D., served as SAMHSA Government Project Officers.

Disclaimer

The views, opinions, and content of this publication are those of the authors and contributors and do not necessarily reflect the views, opinions, or policies of the Center for Mental Health Services (CMHS), SAMHSA, or HHS.

Public Domain Notice

All material appearing in this document is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization from the Office of Communications, SAMHSA, HHS.

Electronic Access and Copies of Publication

This publication may be downloaded or ordered at <http://www.samhsa.gov/shin>. Or, please call SAMHSA's Health Information Network at **1-877-SAMHSA-7** (1-877-726-4727) (English and Español).

Recommended Citation

Substance Abuse and Mental Health Services Administration. *MedTEAM: The Evidence*. HHS Pub. No. SMA-10-4548, Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, 2010.

Originating Office

**Center for Mental Health Services
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road
Rockville, MD 20857**

HHS Publication No. SMA-10-4548
Printed 2010

The Evidence

The Evidence introduces all stakeholders to the research literature and other resources on Medication Treatment, Evaluation, and Management (MedTEAM). This booklet includes the following resources:

- A selected bibliography for further reading;
- References for the citations presented throughout the KIT; and
- Acknowledgements of KIT developers and contributors.

MedTEAM

This KIT is part of a series of Evidence-Based Practices KITs created by the Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services.

This booklet is part of the MedTEAM KIT that includes a DVD, CD-ROM, and seven booklets:

How to Use the Evidence-Based Practices KITs

Getting Started with Evidence-Based Practices

Building Your Program

Training Frontline Staff

Evaluating Your Program

The Evidence

Using Multimedia to Introduce Your EBP



What's in *The Evidence*

Selected Bibliography	1
References	19
Acknowledgments	23

MedTEAM

The Evidence

Selected Bibliography

Antipsychotic polypharmacy

- Ananth, J., Parameswaran, S., & Gunatilake, S. (2004). Antipsychotic polypharmacy. *Current Pharmaceutical Design*, *10*, 2231-2238.
- Canales, P. L., Olsen, J., Miller, A. L., & Crismon, M. L. (1999). Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. *CNS Drugs*, *12*, 179-188.
- Ito, H., Koyama, A., & Higuchi, T. (2005). Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription. *British Journal of Psychiatry*, *187*, 243-247.

- Stahl, S. M. (1999). Antipsychotic polypharmacy, Part I: Therapeutic option or dirty little secret? *Journal of Clinical Psychiatry*, *60*, 425-426.
- Suzuki, T., Uchida, H., Watanabe, K., Yagi, G., & Kashima, H. (2004). A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *28*, 361-369.

Electronic medical records (EMR)

Major, L. F., & Turner, M. G. (2003). Assessing the information management requirements for behavioral health providers. *Journal of Healthcare Management*, 48, 323-333; discussion, 48, 334-335.

Web sites

<http://psychiatry.mc.duke.edu>

The Clinical Research Information System (CRIS) was developed over the past decade by the Duke University School of Medicine Department of Psychiatry and Behavioral Sciences. Not only a true EMR, but also has extensive research and clinical trial capabilities that are being used by top centers in the country and overseas.

<http://www.askesis.com>

A link to the vendor for the PsychConsult product, developed within and used by Western Psychiatric Institute, among others.

<http://www.capterra.com/mental-health-software>

An extensive list of EMR and other electronic (scheduling, notes, prescriptions) software vendors.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14552101&dopt=Abstract

A link for a 2003 paper that discusses assessing behavioral health agency needs for EMR implementation.

Fidelity scales

Bond, G. R., Miller, A. L., Taylor A., Tsai, J., Howard, P. B., El-Mallakh, P., et al. (2007). A scale to assess fidelity to evidence-based principles of medication management for schizophrenia. *Schizophrenia Bulletin*, 33, 469.

Howard, P. B., El-Mallakh, P., Miller, A. L., Rayens, M. K., Bond, G. R., Henderson, K., et al. (2009). Prescriber fidelity to a medication management evidence-based practice in the treatment of schizophrenia. *Psychiatric Services*, 60 (7), 929-935.

Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B., El-Mallakh, P., Finnerty, M., et al. (2009). Scales to evaluate quality of medication management: Development and psychometric properties. *Administration and Policy in Mental Health and Mental Health Services Research*. Published online February 27, 2009. DOI 10.1007/s10488-009-0209-z.

Implementing evidence-based practices

Drake, R. E., Goldman, H. H., Leff, H. S., Lehman, A. F., Dixon, L., Mueser, K. T., et al. (2001). Implementing evidence-based practices in routine mental health service settings. *Psychiatric Services*, 52, 179-182.

Goldman, H. H., Ganju, V., Drake, R. E., Gorman, P., Hogan, M., Hyde, P. S., et al. (2001). Policy implications for implementing evidence-based practices. *Psychiatric Services*, 52, 1591-1597.

Sernyak, M. J. (2007). Implementation of monitoring and management guidelines for second-generation antipsychotics. *Journal of Clinical Psychiatry*, 68(Suppl 4), 14-18.

Torrey, W. C., Drake, R. E., Dixon, L., Burns, B. J., Flynn, L., Rush, J., et al. (2001). Implementing evidence-based practices for persons with severe mental illnesses. *Psychiatric Services*, 52, 45-50.

Williams, T. L., Cerese, J., Cuny, J., & Sama, D. (2008). Outcomes of an initial set of standardized performance measures for inpatient mental health. *Joint Commission Journal on Quality and Patient Safety*, 34, 399-406.

Medication algorithms and guidelines

American Psychiatric Association Schizophrenia Practice Guidelines. (2004). Retrieved from <http://www.psychiatryonline.org>

Canadian Psychiatric Association. (2005, Nov.). Clinical Practice Guidelines: Treatment of Schizophrenia. *Canadian Journal of Psychiatry*, 50(13 Suppl 1), 7S-57S.

International Psychopharmacology Algorithm Project. (2007). <http://www.ipap.org>

Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., et al. (2004). The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003. *Schizophrenia Bulletin*, 30, 193-217.

McEvoy, J. P., Scheifler, P. L., & Frances, A., (Eds.). (1999). The Expert Consensus Guideline Series: Treatment of schizophrenia 1999. *Journal of Clinical Psychiatry*, 60(Suppl 11), 4-80.

Mellman, T. A., Miller, A. L., Weissman, E. M., Crismon, M. L., Essock, S. M., & Marder, S. R. (2001). Evidence-based pharmacologic treatment for people with severe mental illness: A focus on guidelines and algorithms. *Psychiatric Services*, 52, 619-625.

Miller, A. L. (2004). PORT Treatment Recommendations. *Schizophrenia Bulletin*, 30, 601-604.

Moore, T. A., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., et al. (2007). The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. *Journal of Clinical Psychiatry*, 68, 1751-1762.

Texas Department of State Health Services, Texas Medication Algorithm Project (TMAP) and Texas Implementation of Medication Algorithms (TIMA). (2007). *Antipsychotic algorithm for the treatment of schizophrenia*. Available from <http://www.dshs.state.tx.us/mhprograms/TIMA.shtml>

Medications for schizophrenia

- Baldessarini, R. J., Gardener, D. M., & Garver, D. L. (1995). Conversions from clozapine to other antipsychotic drugs [Letter to the editor]. *Archives of General Psychiatry*, 52, 1071-1072.
- Bell, R., McLaren, A., Gaionos, J., and Copolov, D. (1998). The clinical use of plasma clozapine levels. *Australian and New Zealand Journal of Psychiatry*, 32, 567-574.
- Buckley, P. F. (1999). The role of typical and atypical antipsychotic medications in the management of agitation and aggression. *Journal of Clinical Psychiatry*, 60(Suppl 10), 52-60.
- Buckley, P., Miller, A., Olsen, J., Garver, D., Miller, D. D., & Csernansky, J. (2001). *When symptoms persist: Clozapine augmentation strategies*. *Schizophrenia Bulletin*, 27, 615-628.
- Carnahan, R. M., Lund, B. C., & Perry, P. J. (2001). Ziprasidone, A new atypical antipsychotic drug. *Pharmacotherapy*, 21, 717-730.
- Chang, H. H., & Berman, I. (1999). Treatment issues for consumers with schizophrenia who have obsessive-compulsive symptoms. *Psychiatric Annals*, 29, 529-532.
- Conley, R. R., & Mahmoud, R. (2001). A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. *American Journal of Psychiatry*, 158, 765-774.
- Conley, R. R., Tamminga, C.A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., et al. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. *American Journal of Psychiatry*, 155, 914-920.
- Gilbert, P. L., Harris, M. J., McAdams, L. A., & Jeste, D. V. (1995). Neuroleptic withdrawal in schizophrenia patients: A review of the literature. *Archives of General Psychiatry*, 52, 173-188.
- Janicak, P. G., Davis, J. M., Preskorn, S. H., Ayd, F. J., Jr., Marder, S. R., & Pavuluri, M. N. (2006). *Principles and Practice of Psychopharmacotherapy* (4th ed.). Baltimore: Lippincott, Williams & Wilkins.
- Jayaram, M. B., Hosalli, P., & Stroup, T. S. (2006). Risperidone versus olanzapine for schizophrenia. *Cochrane Database of Systematic Reviews*, (2), Art. No.: CD005237. DOI: 10.1002/14651858.CD005237.pub2.
- Kinghorn, W. A., & McEvoy, J. P. (2005). Aripiprazole: Pharmacology, efficacy, safety and tolerability. *Expert Review of Neurotherapeutics*, 5, 297-307.
- Lieberman, J. A., Safferman, A. Z., Pollack, S., Szymanski, S., Johns, C., Howard, A., et al. (1994). Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. *American Journal of Psychiatry*, 151, 1744-1752.
- Lindenmayer, J. P., & Khan, A. (2004). Pharmacological treatment strategies for schizophrenia. *Expert Review of Neurotherapeutics*, 4, 705-723.
- Lindenmayer, J. P., Khan, A., Iskander, A., Abad, M. T., & Parker, B. (2007). A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. *Journal of Clinical Psychiatry*, 68, 368-379.

- Luft, B., & Taylor, D. (2006). A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. *Expert Opinion on Pharmacotherapy*, 7, 1739-1748.
- Marder, S. R. (2000). Schizophrenia: Somatic treatment. In B. J. Sadock and V. A. Sadock (Eds.), *Comprehensive textbook of psychiatry VII* (pp. 1199-1210). Philadelphia: Lippincott, Williams & Wilkins: 1199-1210.
- Meltzer, H. Y., & Bobo, W. V. (2006). Interpreting the efficacy findings in the CATIE study: What clinicians should know. *CNS Spectrums*, 11(7 Suppl 7), 14-24.
- Meyer, J. M. (2007). Antipsychotic safety and efficacy concerns. *Journal of Clinical Psychiatry*, 68(Suppl 14), 20-26.
- Miller, A. L., Dassori, A., Ereshefsky, L., & Crismon, M. L. (2001). Recent issues and developments in antipsychotic use. In D. L. Dunner & J. F. Rosenbaum (Eds.), *Psychiatric clinics of North America annual of drug therapy* (pp. 209-235). Philadelphia: W. B. Saunders Company.
- Miller, A. L., McEvoy, J. P., Jeste, D., & Marder, S. (2006). Treatment of chronic schizophrenia. In J. A. Lieberman, T. S. Stroup, & D. O. Perkins (Eds.), *Textbook of schizophrenia* (pp. 365-381). Arlington, VA: American Psychiatric Publishing, Inc.
- Reznik, I., & Sirota, P. (2000). Obsessive and compulsive symptoms in schizophrenia: A randomized controlled trial with fluvoxamine and neuroleptics. *Journal of Clinical Psychopharmacology*, 20, 410-416.
- Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P. et al. (1997). Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. *British Journal of Psychiatry*, 171, 569-573.
- Siris, S. G. (2000). Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents. *American Journal of Psychiatry*, 157, 1379-1389.
- Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., et al. (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *American Journal of Psychiatry*, 163, 611-622.
- Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., et al. (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. *American Journal of Psychiatry*, 164, 415-427.
- Tandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, Jr., J. J., Okasha, A., Singh, B., et al. (2008). World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophrenia Research*, 100, 20-38.
- Thompson, C. (1994). The use of high-dose antipsychotic medication. *British Journal of Psychiatry*, 164, 448-458.
- Viguera, A. C., Baldessarini, R. J., Hegarty, J. D., van Kammen, D. P., & Tohen, M. (1997). Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. *Archives of General Psychiatry*, 54, 49-55.
- Yen, Y.-C., Lung, F. W., & Chong, M. Y. (2004). Adverse effects of risperidone and haloperidol treatment in schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 28, 285-290.

Medication update Web sites and newsletters

Biological Therapies in Psychiatry.

<http://www.btpnews.com>

Child & Adolescent Psychiatry Alerts.

<http://www.alertpubs.com/child.htm>

Current Psychiatry.

<http://www.currentpsychiatry.com>

Epocrates. Online—Free drug and clinical reference for the web browser.

<http://www.epocrates.com/products/online/index.html>

Evidence-Based Answers to Clinical Questions for Busy Clinicians (2009). The Centre for Clinical Effectiveness, Southern Health, at the Monash Institute of Health Services Research, Melbourne, Australia.

http://www.southernhealth.org.au/icms_docs/2145_EBP_workbook.pdf

Food and Drug Administration: Drugs@FDA.

<http://www.accessdata.fda.gov/scripts/cder/drugsatfda>

Food and Drug Administration: Center for Drug Evaluation and Research.

<http://www.fda.gov/cder/drug/default.htm>

Indiana University, Division of Clinical Pharmacology: Drug Interaction Table (Cytochrome P450 System).

<http://medicine.iupui.edu/flockhart>

International Bibliographic Information on Dietary Supplements (IBIDS).

http://ods.od.nih.gov/Health_Information/IBIDS.aspx

Journal Watch: Psychiatry.

<http://psychiatry.jwatch.org>

MedlinePlus: Medicines.

<http://www.nlm.nih.gov/medlineplus/medicines.html>

Psychiatry Drug Alerts.

<http://www.alertpubs.com/Psych.htm>

Psychiatry Weekly.

<http://www.psychiatryweekly.com>

Psychopharm Review (formerly *International Drug Therapy Newsletter*).

<http://www.lww.com/resources/cmeinfo/internationaldrugtherapy.html>

The Brown University Child and Adolescent Psychopharmacology Update.

<http://www.wiley.com/WileyCDA/WileyTitle/productCd-CPU.html>

The Brown University Geriatric Psychopharmacology Update.

<http://www.wiley.com/WileyCDA/WileyTitle/productCd-GPU.html>

The Brown University Psychopharmacology Update.

<http://www.wiley.com/WileyCDA/WileyTitle/productCd-PU.html>

The Carlat Psychiatry Report.

<http://www.thecarlatreport.com>

Quality of medication management and documentation

- Adams, A. S., Soumerai, S. B., Lomas, J., & Ross-Degnan, D. (1999). Evidence of self-report bias in assessing adherence to guidelines. *International Journal for Quality in Health Care, 11*, 187-192.
- American Psychiatric Association. (2004). *Practice guideline for the treatment of patients with schizophrenia* (2nd ed.). Arlington, VA: Author.
- Bollini, P., Pampallona, S., Nieddu, S., Bianco, M., Tibaldi, G., & Munizza, C. (2008). Indicators of conformance with guidelines of schizophrenia treatment in mental health services. *Psychiatric Services, 59*, 782-791.
- Cradock, J., Young, A. S., et al. (2001). The accuracy of medical record documentation in schizophrenia. *Journal of Behavioral Health Services and Research, 28*, 456-465.
- Lehman, A. F. (1999). Improving treatment for persons with schizophrenia. *Psychiatric Quarterly, 70*, 259-272.
- Lehman, A. F., Steinwachs, D. M., & the Co-Investigators of the PORT Project. (1998). Translating research into practice: The schizophrenia PORT treatment recommendations. *Schizophrenia Bulletin, 24*, 1-10.
- Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., et al. (2002). The Mount Sinai conference on the pharmacotherapy of schizophrenia. *Schizophrenia Bulletin, 28*, 5-16.
- Owen, R. R., Thrush, C. R., Hudson, T. J., Mallory, S. R., Fischer, E. P., Clardy, J. A., et al. (2002). Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia. *International Journal for Quality in Health Care, 14*, 199-206.
- Rush, A. J., Rago, W. V., Crismon, M. L., Toprac, M. G., Shon, S. P., Suppes, T., et al. (1999). Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project. *Journal of Clinical Psychiatry, 60*, 284-291.
- Smith, T. E., & Docherty, J. P. (1998). Standards of care and clinical algorithms for treating schizophrenia. *Psychiatric Clinics of North America, 21*, 203-220.
- Uttaro, T., Finnerty, M., White, T., Gaylor, R., & Shindelman, L. (2007). Reduction of concurrent antipsychotic prescribing practices through the use of PSYCKES. *Administration and Policy in Mental Health and Mental Health Services Research, 34*, 57-61.
- Young, A. S., Sullivan, G., Burnam, M. A., & Brook, R. H. (1998). Measuring the quality of outpatient treatment for schizophrenia. *Archives of General Psychiatry, 55*, 611-617.

Racial and ethnic effects on medication management

- Frackiewicz, E. J., Sramek, J. J., Herrera, J. M., Kurtz, N., & Cutler, N. R. (1997). Ethnicity and antipsychotic response. *Annals of Pharmacotherapy*, *31*, 1360-1369.
- Leckband, S. G., Bishop, J. R., & Ellingrod, V. L. (2007). Pharmacogenomics in psychiatry. *Journal of Pharmacy Practice*, *20*, 252-264.
- Malhotra, A. K., Murphy, G. M., & Kennedy, J. L. (2004). Pharmacogenetics of psychotropic drug response. *American Journal of Psychiatry*, *161*, 780-796.
- Ng, C. H., Chong, S. A., Lambert, T., Fan, A., Hackett, L. P., & Mahendran, R. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response, and plasma levels. *International Clinical Psychopharmacology*, *20*, 163-168.
- U.S. Department of Health and Human Services. (2001). *Mental health: Culture, race, and ethnicity— A supplement to mental health: A report of the Surgeon General*. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services.

Recovery and remission

- Allott, P., Loganathan, L., & Fulford, K. W. M. (2002). Discovering hope for recovery: A review of a selection of recovery literature, implications for practice and systems change. *Canadian Journal of Community Mental Health*, *21*, 13-33.
- American Psychiatric Association (2005). *Use of the concept of recovery: Position statement* Arlington, VA: Author. Retrieved from <http://www.psych.org/Departments/EDU/Library/APAOfficialDocumentsandRelated/PositionStatements/200504.aspx>
- Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005). Remission in schizophrenia: Proposed criteria and rationale for consensus. *American Journal of Psychiatry*, *162*, 441-449.
- Anthony, W., Rogers, E. S., & Farkas, M. (2003). Research on evidence-based practices: Future directions in an era of recovery. *Community Mental Health Journal*, *39*, 101-114.
- Campbell-Orde, T., Chamberlin, J., Carpenter, J., & Leff, H. S. (Eds.). (2005). *Measuring the promise: A compendium of recovery measures* (Vol. II). (Publication No. 55). Cambridge, MA: The Evaluation Center @ Human Services Research Institute.
- Center for Mental Health Services. (2005). *National consensus statement on mental health recovery* (Publication No. SMA-05-4129). Rockville, MD: Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services.

- Copeland, Mary Ellen. (1997). *Wellness Recovery Action Plan*. West Dummerston, VT: Peach Press.
- Davidson, L., Schmutte, T., Dinzeo, T., & Andres-Hyman, R. (2008). Remission and recovery in schizophrenia: Practitioner and patient perspectives. *Schizophrenia Bulletin*, 34:5-8.
- Del Vecchio, P., & Blyler, C. R. (2009). Identifying critical outcomes and setting priorities for mental health services research. In J. Wallcraft, B. Schrank, & M. Amering (Eds.), *Handbook of service user involvement in mental health research* (pp. 99-112). Hoboken, NJ: Wiley-Blackwell.
- Dumont, J. M., Ridgway, P., Onken, S. J., Dornan, D. H., & Ralph, R. O. (2006). *Mental health recovery: What helps and what hinders? A national research project for the development of recovery facilitating system performance indicators*. Alexandria, VA: National Association of State Mental Health Program Directors, National Technical Assistance Center for State Mental Health Planning.
- Evaluation Center @ Human Services Research Institute. (2007). *Addendum to measuring the promise: A compendium of recovery measures, Volume II*. Cambridge, MA: Author.
- Farkas, M., Gagne, C., Anthony, W., & Chamberlin, J. (2005). Implementing recovery oriented evidence based programs: Identifying the critical dimensions. *Community Mental Health Journal*, 41, 141-158.
- Jacobson, N. (2004). *In recovery: The making of mental health policy*. Nashville, TN: Vanderbilt University Press.
- Kane, J. M. (2008). An evidence-based strategy for remission in schizophrenia. *Journal of Clinical Psychiatry*, 69(Suppl 3), 25-30.
- Ralph, R. O., Kidder, K., & Phillips, D. (2000). *Can we measure recovery? A compendium of recovery and recovery-related instruments* (Publication No. 43). Cambridge, MA: The Evaluation Center @ Human Services Research Institute.
- Ralph, Ruth O. (2000). *Review of recovery literature: A synthesis of a sample of recovery Literature 2000*. Alexandria, VA: National Association of State Mental Health Program Directors, National Technical Assistance Center for State Mental Health Planning.
- Ralph, R. O., Lambert, D., & Kidder, K. A. (2002). *Recovery perspective and evidence-based practice for people with serious mental illness: A guideline developed for the Behavioral Health Recovery Management Project*. An Initiative of Fayette Companies, Peoria, IL; Chestnut Health Systems, Bloomington, IL; and the University of Chicago Center for Psychiatric Rehabilitation. Retrieved from <http://www.bhrm.org/guidelines/Ralph%20Recovery.pdf>
- Ridgway, P. (2001). Restoring psychiatric disability: Learning from first person recovery narratives. *Psychiatric Rehabilitation Journal*, 24, 335-344.
- Sowers, W. (2005). Transforming systems of care: The American Association of Community Psychiatrists Guidelines for Recovery Oriented Services. *Community Mental Health Journal*, 41, 757-774.
- Young, S. L., & Ensing, D. S. (1999). Exploring recovery from the perspective of people with psychiatric disabilities. *Psychiatric Rehabilitation Journal*, 22, 219-231.

Shared decisionmaking and adherence

- Adams, N., & Grieder, D. (2004). *Treatment planning for person-centered care: The road to mental health and addiction recovery*. Burlington, Massachusetts: Elsevier Academic Press.
- Adams, J., & Scott, J. (2000). Predicting medication adherence in severe mental disorders. *Acta Psychiatrica Scandinavica*, *101*, 119-124.
- Agarwal, M. R., Sharma, V. K., Kishore Kumar, K. V., & Lowe, D. (1998). Non-compliance with treatment in patients suffering from schizophrenia: A study to evaluate possible contributing factors. *International Journal of Social Psychiatry*, *44*, 92-106.
- Byerly, M. J., Nakonezny, P. A., & Rush, A. J. (2008). The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. *Schizophrenia Research*, *100*, 60-69.
- Charles, C., Gafni, A., & Whelan, T. (1997). Shared decision-making in the medical encounter: What does it mean? (Or it takes at least two to tango). *Social Science & Medicine*, *44*, 681-692.
- Corrigan, P. W., Liberman R. P., & Engel, J. D. (1990). From noncompliance to collaboration in the treatment of schizophrenia. *Hospital & Community Psychiatry*, *41*, 1203-1211.
- Cramer, J. A., & Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. *Psychiatric Services*, *49*, 196-201.
- Deegan, P. E., Rapp, C., Holter, M., & Riefer, M. (2008). Best practices: A program to support shared decision making in an outpatient psychiatric medication clinic. *Psychiatric Services*, *59*, 603-605.
- Elwyn, G., Edwards, A., Gwyn, R., & Grol, R. (1999). Towards a feasible model for shared decision-making: Focus group study with general practice registrars. *BMJ*, *319*, 753-756.
- Fallon, I. R. H. (1984). Developing and maintaining adherence to long-term drug-taking regimens. *Schizophrenia Bulletin*, *10*, 412-417.
- Frank, A. F., & Gunderson, J. G. (1990). The role of the therapeutic alliance in the treatment of schizophrenia: Relationship to course and outcome. *Archives of General Psychiatry*, *47*, 228-236.
- Frosch, D. L., & Kaplan, R. M. (1999). Shared decision-making in clinical medicine: Past research and future directions. *American Journal of Preventive Medicine*, *17*, 285-294.
- Garavan, J., Browne, S. Gervin, M., Lane, A., Larkin, C., & O'Callaghan, E. (1998). Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. *Comprehensive Psychiatry*, *39*, 215-219.
- Kelly, G. R., & Scott, J. A. (1990). Medication compliance and health education among outpatients with chronic mental disorders. *Medical Care*, *28*, 1181-1197.
- Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998). Randomised controlled trial of compliance therapy—18 month follow-up. *British Journal of Psychiatry*, *172*, 413-419.

- Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. *Journal of Clinical Psychiatry*, 63, 892-909.
- Masand, P. S., & Narasimhan, M. (2006). Improving adherence to antipsychotic pharmacotherapy. *Current Clinical Pharmacology*, 1, 47-56.
- Macpherson, R., Jerrom, B., & Hughes, A. (1996). A controlled study of education about drug treatment in schizophrenia. *British Journal of Psychiatry*, 168, 709-717.
- Nosé, M., Barbui, C., & Tansella, M. (2003). How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. *Psychological Medicine*, 33, 1149-1160. Published online 9/27/03. Available from <http://journals.cambridge.org>
- Olfson, M., Mechanic, D., Hansell, S., Boyer, C. A., Walkup, J., & Weiden, P. J. (2000). Predicting medication noncompliance after hospital discharge among patients with schizophrenia. *Psychiatric Services*, 51, 216-222.
- Perkins, D. O., Johnson, J. L., Hamer, R. M., Zipursky, R. B., Keefe, R. S., Centorrino, F., et al. (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. *Schizophrenia Research*, 83, 53-63.
- Ruscher, S. M., de Wit, R., & Mazmanian, D. (1997). Psychiatric patients' attitudes about medication and factors affecting noncompliance. *Psychiatric Services*, 48, 82-85.
- Stevenson, F. A., Barry, C. A., Britten, N., Barber, N., & Bradley, C. P. (2000). Doctor-patient communication about drugs: The evidence for shared decision-making. *Social Science & Medicine*, 50, 829-840.
- Tay, S. E. (2007). Compliance therapy: An intervention to improve inpatients' attitudes toward treatment. *Journal of Psychosocial Nursing and Mental Health Services*, 45, 29-37.
- Uzenoff, S. R., Perkins, D. O., Hamer, R. M., Wiesen, C. M., & Penn, D. L. (2008). A preliminary trial of adherence-coping-education (ACE) therapy for early psychosis. *Journal of Nervous and Mental Disease*, 196, 572-575.
- Van Putten, T., & May, R. A. (1978). Subjective response as a predictor of outcome in pharmacotherapy. *Archives of General Psychiatry*, 35, 477-480.
- Van Putten, T., May, P. R. A., Marder, S. R., & Wittmann, L. A. (1981). Subjective response to antipsychotic drugs. *Archives of General Psychiatry*, 38, 187-190.
- Velligan, D. I., Diamond, P. M., Mintz, J., Maples, N., Li, X., Zeber, J., et al. (2008). The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. *Schizophrenia Bulletin*, 34, 483-493.
- Velligan, D. I., Lam, F., Ereshefsky, L., & Miller, A. L. (2003). Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. *Psychiatric Services*, 54, 665-667.
- Velligan, D., Lam, Y. W. F., Glahn, D. C., Barrett, J. A., Maples, N. J., Ereshefsky, L., et al. (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. *Schizophrenia Bulletin*, 32, 724-742.
- Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., et al. (2007). Relationships among subjective and objective measures of adherence to oral antipsychotic medications. *Psychiatric Services*, 58, 1187-1192.

Side effects of antipsychotic medication

- American Diabetes Association Clinical Practice Recommendations 2009. (2009). *Diabetes Care*, 32, S1-97.
- American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care*, 27, 596-601.
- Birkenaes, A. B., Birkeland, K. I., Engh, J. A., Færden, A., Jonsdottir, H., Ringen, P. A., et al. (2008). Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. *Journal of Clinical Psychopharmacology*, 28, 132-137.
- Byerly, M., Suppes, T., Tran, Q. V., & Baker, R. A. (2007). Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives. *Journal of Clinical Psychopharmacology*, 27, 639-661.
- Drici, M. D., & Priori, S. (2007) Cardiovascular risks of atypical antipsychotic drug treatment. *Pharmacoepidemiology & Drug Safety*, 16, 882-890.
- Glassman, A. H., & Bigger, J. T. (2001). Antipsychotic drugs: Prolonged QTC interval, torsade de pointes, and sudden death. *American Journal of Psychiatry*, 158, 1774-1782.
- Henderson, D. C., Nguyen, D. D., Copeland, P. M., Hayden, D. L., Borba, C. P., Louie, P. M., et al. (2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. *Journal of Clinical Psychiatry*, 66, 1116-1121.
- Hummer, M., & Huber, J. (2004). Hyperprolactinaemia and antipsychotic therapy in schizophrenia. *Current Medical Research & Opinion*, 20, 189-197.
- Iqbal, M. M., Rahman, A., Husain, Z., Mahmud, S. Z., Ryan, W. F., & Feldman, J. M. (2003). Clozapine: A clinical review of adverse effects and management. *Annals of Clinical Psychiatry*, 15, 33-48.
- Juvonen, H., Reunanen, A., Haukka, J., Mukonen, M. Suvisaari, J., Arajärvi, R., et al. (2007). Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. *Archives of General Psychiatry*, 64, 894-899.
- Kennedy, A., Tapp, A., Kelly, W. S., Kilzieh, N., & Wood, A. E. (2006). Abstinence, anticipation, reduction, and treatment (AART): A stepwise approach to the management of atypical antipsychotic side effects. *Essential Psychopharmacology*, 7, 1-14.
- Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelan, B., & Brecher, M. (1999). Prolactin levels and adverse effects in patients treated with risperidone. *Journal of Clinical Psychopharmacology*, 19, 57-61.
- Lamberti, J. S., Costea, G. O., Olson, D., Crilly, J. F., Maharaj, K., Tu, X., et al. (2005). Diabetes mellitus among outpatients receiving clozapine: Prevalence and clinical-demographic correlates. *Journal of Clinical Psychiatry*, 66, 900-906.
- Leslie, D. L., & Rosenheck, R. A. (2004). Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. *American Journal of Psychiatry*, 161, 1709-1711.
- Malhotra, S., & McElroy, S. L. (2002). Medical management of obesity associated with mental disorders. *Journal of Clinical Psychiatry*, 63(Suppl 4), 24-32.

- Melkersson, K. I., Dahl, M. L., & Hulting, A. L. (2004). Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. *Psychopharmacology*, *175*, 1-6.
- Mortensen, P. B., and Eaton, W. W. (2008). Diabetes mellitus and schizophrenia. *Archives of General Psychiatry*, *65*, 237-238.
- Murashita, M., Inoue, T., Kusumi, I., Nakagawa, S., Itoh, K., Tanaka, T., et al. (2007). Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. *Psychiatry and Clinical Neurosciences*, *61*, 54-58.
- Nakajima, M., Terao, T., Iwata, N., & Nakamura, J. (2005). Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: Effects on hyperprolactinemia. *Pharmacopsychiatry*, *38*, 17-19.
- Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., et al. (2006). Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. *Schizophrenia Research*, *86*, 15-22.
- Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. *Archives of General Psychiatry*, *59*, 337-345.
- Parks J., Svendsen, D., Singer, P., & Foti, M. E. (Eds.) (2006). *Morbidity and mortality in people with serious mental illness*. [Thirteenth in a series of technical reports.] Alexandria, VA: National Association of State Mental Health Program Directors (NAS. H.D) Medical Directors Council Available from <http://www.nasmhpd.org>
- Reinstein, M. J., Sirotovskaia, L. A., Jones, L. E., Mohan, S., & Chasanov, M. A. (1999). Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: Preliminary findings. *Clinical Drug Investigations*, *18*, 99-104.
- Shirzadi, A. A., & Ghaemi, S. N. (2006). Side effects of atypical antipsychotics: Extrapyramidal symptoms and the metabolic syndrome. *Harvard Review of Psychiatry*, *14*, 152-164.
- Srihari, V. H., Tek, C., Chwastiak, L. A., Woods, S. W., & Steiner, J. L. (2007). Best practices: Surveillance and management of diabetes in a CMHC Population. *Psychiatric Services*, *58*, 1151-1153.

Special topics

- Altshuler, L., Hendrick, V., & Cohen, L. S. (1998). Course of mood and anxiety disorders during pregnancy and the postpartum period. *Journal of Clinical Psychiatry*, 59(Suppl 2), 29-33.
- Altshuler, L. L., Cohen L., Szuba, M. P., Burt, V. K., Gitlin, M., & Mintz, J. (1996). Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. *American Journal of Psychiatry*, 153, 592-606.
- Altshuler, L. L., Cohen, L. S., Moline, M. L., Kahn, D. A., Carpenter, D., & Docherty, J. P. (2001). Treatment of depression in women (Consensus Guideline Series). *Postgraduate Medicine* (special report), 1-107.
- American Academy of Pediatrics, Committee on Drugs. (2000). Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. *Pediatrics*, 105, 880-887.
- Arango, C., Parellada, M., & Moreno, D. M. (2004). Clinical effectiveness of new generation antipsychotics in adolescent patients. *European Neuropsychopharmacology*, 14(Suppl 4), S471-479.
- Briggs, G. G., Freeman, R. K., & Yaffe, S. J. (2008). *Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk*, (8th ed). Philadelphia: Lippincott, Williams & Wilkins.
- Briggs Update: Drugs in Pregnancy and Lactation*. Available from <http://www.briggsdrugsinpregnancy.com>
- Bupropion Pregnancy Registry Final Report*. (2008). A project of Glaxo-SmithKline. Available from <http://pregnancyregistry.gsk.com/bupropion.html>
- Byerly, M. J., Weber, M. T., Brooks, D. L., Snow, L. R., Worley, M. A., & Lescouffeur, E., et al. (2001). Antipsychotic medications and the elderly: Effects on cognition and implications for use. *Drugs & Aging*, 18, 45-61.
- Centre for Addiction and Mental Health (CAMH). (2007). *Psychotropic medications and other substances during pregnancy and lactation: A handbook for health care providers*. Toronto, Ontario, Canada: Author. Available from http://www.camh.net/Publications/Resources_for_Professionals/Pregnancy_Lactation/index.html
- Chambers, C. (1996). Birth outcomes in pregnant women taking fluoxetine. *New England Journal of Medicine*, 335, 1010-1015.
- Cohen, L. S., & Rosenbaum, J. F. (1998). Psychotropic drug use during pregnancy: Weighing the risks. *Journal of Clinical Psychiatry*, 59(Suppl 2), 18-28.
- Craig, M., & Abel, K. (2001). Prescribing for psychiatric disorders in pregnancy and lactation. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 15, 1013-1030.
- D. V.ne, C. L., & Nemeroff, C. B. (1999). Psychotropic drug interactions. In R. G. Robinson and W. R. Yates (Eds.), *Psychiatric treatment of the mentally ill* (pp. 523-543). New York: Marcel Dekker, Inc.
- Ernst, C. L., & Goldberg, J. F. (2002). The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. *Journal of Clinical Psychiatry*, 63(Suppl 4), 42-55.
- Gold, L. H. (2000). Use of psychotropic medication during pregnancy: Risk management guidelines. *Psychiatric Annals*, 30, 421-432.

- Goldstein, D. J., & Corbin, L. A. (2000). Olanzapine-exposed pregnancies and lactation: Early experience. *Journal of Clinical Psychopharmacology*, *20*, 399-403.
- Ito, S. (2000). Drug therapy for breast-feeding women. *New England Journal of Medicine*, *343*, 118-126; erratum, *343*, 1348.
- Koren, G., Cohen, T., Chitayat, D., Kapur, B., Remington, G., Reid, D. M., et al. (2002). Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. *American Journal of Psychiatry*, *159*, 136-137.
- Lamotrigine Pregnancy Registry*. A project conducted by Glaxo-SmithKline. <http://pregnancyregistry.gsk.com/lamotrigine.html>
- Lane, H. Y., Jann, M. W., Chang, Y. C., Chiu, C. C., Huang, M. C., Lee, S. H., et al. (2001). Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. *Journal of Clinical Psychiatry*, *62*, 812-817.
- Llewellyn, A., & Stowe, Z. N. (1998). Psychotropic medications in lactation. *Journal of Clinical Psychiatry*, *59*(Suppl 2), 41-52.
- Masand, P. S., & Gupta, S. (2003). Long-acting injectable antipsychotics in the elderly: Guidelines for effective use. *Drugs & Aging*, *20*, 1099-1110.
- McCarthy, R. H. (1994). Seizures following smoking cessation in a clozapine responder. *Pharmacopsychiatry*, *27*, 210-11.
- McKenna, K., Koren, G., Tetelbaum, M., Wilton, L., Shakir, S., Diav-Citrin, O., et al. (2005). Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. *Journal of Clinical Psychiatry*, *66*, 444-449.
- Mintzer, J., & Targum, S. D. (2003). Psychosis in elderly patients: Classification and pharmacotherapy. *Journal of Geriatric Psychiatry and Neurology*, *16*, 199-206.
- Mortola, J. F. (1989). The use of psychotropic agents in pregnancy and lactation. *Psychiatric Clinics of North America*, *12*, 69-87.
- Newport, D. J., Calamaras, M. R., D. V.ne, C. L., Donovan, J., Beach, A. J., Winn, S., et al. (2007). Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. *American Journal of Psychiatry*, *164*, 1214-1220.
- Nonacs, R., & Cohen, L. S. (1998). Postpartum mood disorders: Diagnosis and treatment guidelines. *Journal of Clinical Psychiatry*, *59*(Suppl 2), 34-40.
- Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., & Theis, J. G. W. (1997). Neurodevelopment of children exposed in utero to antidepressant drugs. *New England Journal of Medicine*, *336*, 258-262.
- Ordean, A., Midmer, D., Graves, L., Payne, S., Hunt, G., & the PRIMA Group. (2008). *Pregnancy-Related Issues in the Management of Addictions (PRIMA)*. A reference for care providers. Ontario, Canada: University of Toronto, Department of Family and Community Medicine, Retrieved from <http://www.addictionpregnancy.ca>
- Organization of Teratology Information Specialists. <http://otispregnancy.org>
- Patton, S. W., Misri, S., Corral, M. R., Perry, K. F., and Kuan, & A. F. (2002). Antipsychotic medication during pregnancy and lactation in women with schizophrenia: Evaluating the risk. *Canadian Journal of Psychiatry*, *47*, 959-965.

Drugs in Pregnancy and Breastfeeding.

[Web page]. <http://www.perinatology.com/exposures/druglist.htm>

Schou, M. (1990). Lithium treatment during pregnancy, delivery, and lactation: An update. *Journal of Clinical Psychiatry, 51*, 410-413.

Toren, P., Ratner, S., Laor, N., & Weizman, A. (2004). Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. *Drug Safety, 27*, 1135-1156.

Toxicology Data Network: LactMed: Drugs and Lactation Database. Available from <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT>

Trixler, M., Gáti, A., Fekete, S., & Tényi, T. (2005). Use of antipsychotics in the management of schizophrenia during pregnancy. *Drugs, 65*, 1193-1206.

Viguera, A. C., Cohen, L. S., Baldessarini, R. J., & Nonacs, R. (2002). Managing bipolar disorder during pregnancy: Weighing the risks and benefits. *Canadian Journal of Psychiatry, 47*, 426-436.

Yaeger, D., Smith, H. G., & Altshuler, L. L. (2006). Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. *American Journal of Psychiatry, 163*, 2064-2070.

Yogev, Y., Ben-Haroush, A., & Kaplan, B. (2002). Maternal clozapine treatment and decreased fetal heart rate variability. *International Journal of Gynecology & Obstetrics, 79*, 259-260.

Symptom assessment

Bell, M., Fiszdon, J., Richardson, R. Lysaker, P., & Bryson, G. (2007). Are self-reports valid for schizophrenia patients with poor insight? Relationship of unawareness of illness to psychological self-report instruments. *Psychiatry Research, 151*, 37-46.

Niv, N., Cohen, A. N., Mintz, J., Ventura, J., & Young, A.S. (2007). The validity of using patient self-report to assess psychotic symptoms in schizophrenia. *Schizophrenia Research, 90*, 245-250.

Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.). (2008). *Handbook of psychiatric measures* (2nd ed.). Arlington, VA: American Psychiatric Publishing, Inc.

Sajatovic, M., & Ramirez, L. F. (2003). *Rating scales in mental health* (2nd ed.). Hudson, Ohio: Lexi-Comp, Inc.

Treatment-resistant schizophrenia

- Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. *Archives of General Psychiatry*, *45*, 789-796.
- Kelly, D. L., Conley, R. R., Richardson, C. M., Tamminga, C. A., & Carpenter, W. T. (2003). Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. *Annals of Clinical Psychiatry*, *15*, 181-186.
- Lerner, V., Libov, I., Kotler, M., & Strous, R. D. (2004). Combination of “atypical” antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *28*, 89-98.
- McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *American Journal of Psychiatry*, *163*, 600-610.
- Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., et al. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *New England Journal of Medicine*, *337*, 809-815.

The Evidence

References

The following list includes the references for all citations in the KIT.

Arranz, M. J., & de Leon, J. (2007). Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. *Molecular Psychiatry*, 12, 707-747.

Bauer, M. S. (2002). A review of quantitative studies of adherence to mental health clinical practice guidelines. *Harvard Review of Psychiatry*, 10, 138-153.

Becker, D. R., Bond, G. R., McCarthy, D., Thompson, D., Xie, H., McHugo, G. J., et al. (2001). Converting day treatment centers to supported employment programs in Rhode Island. *Psychiatric Services*, 52, 351-357.

Bond, G. R., & Salyers, M. P. (2004). Prediction of outcome from the Dartmouth Assertive Community Treatment Fidelity Scale. *CNS Spectrums*, 9, 937-942.

Cabana, M. D., Rand, C. S., Powe, N. R., Wu, A. W., Wilson, M. H., Abboud, P. A. C., et al. (1999). Why don't physicians follow clinical practice guidelines? A framework for improvement. *Journal of the American Medical Association*, 282, 1458-1465.

Carbamazepine package insert. See <http://www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf>

- Cradock, J., Young, A. S., & Sullivan, G. (2001). The accuracy of medical record documentation in schizophrenia. *Journal of Behavioral Health Services & Research*, 28, 456-465.
- Drake, R. E., Bond, G. R., & Rapp, C. A. (2006). Explaining the variance within supported employment programs: Comment on “what predicts supported employment outcomes?” *Community Mental Health Journal*, 42, 315-318.
- Frackiewicz, E. J., Herrera, J. M., Sramek, J. J., Collazo, I. Y., & Lawson, W. B. (2002). Risperidone in the treatment of Hispanic inpatients with schizophrenia: A pilot study. *Psychiatry* 65(4): 371-374.
- Ferris, F. D., & Librach, S. L. (2005). Models, standards, guidelines. *Clinics in Geriatric Medicine*, 21, 17-44.
- Ganju, V. (2004, June). *Evidence-based practices: Responding to the challenge*. Presented at the NAS. H.D Commissioner’s Meeting, San Francisco, CA.
- Howard, P. B., El-Mallakh, P., Miller, A. L., Rayens, M. K., Bond, G. R., Henderson, K., et al. (2009). Prescriber fidelity to a medication management evidence-based practice in the treatment of schizophrenia. *Psychiatric Services*, 60, 929-935.
- Hyde, P. S., Falls, K., Morris, J. A., & Schoenwald, S. K. (2003). *Turning knowledge into practice: A manual for behavioral health administrators and practitioners about understanding and implementing evidence-based practices*. Boston: Technical Assistance Collaborative. Available from <http://www.tacinc.org>
- Institute of Medicine. (2006). Improving the quality of health care for mental and substance-use conditions: *Quality Chasm Series*. Washington, DC: National Academy of Sciences.
- Katon, W., Von Korff, M., Lin, E., Walker, E., Simon, G. E., Bush, T., et al. (1995). Collaborative management to achieve treatment guidelines: Impact on depression in primary care. *Journal of the American Medical Association*, 273, 1026-1031.
- Lehman, A. F., & Steinwachs, D. M. (1998). Patterns of usual care for schizophrenia: Initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. *Schizophrenia Bulletin*, 24, 11-20.
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R., Perkins, D. O., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine*, 353, 1209-1223.
- Lin, K. M., & Funder, E. (1983). Neuroleptic dosage for Asians. *American Journal of Psychiatry*, 140, 490-491.
- Lindenmayer, J. P., Volavka, J., Lieberman, J., Sheitman, B., Citrome, L., Chakos, M., et al. (2001). Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial. *Journal of Clinical Psychopharmacology*, 21, 448-453.
- Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., et al. (2002). The Mount Sinai Conference on the pharmacotherapy of schizophrenia. *Schizophrenia Bulletin*, 28, 5-16.
- Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., et al. (2004). Physical health monitoring of patients with schizophrenia. *American Journal of Psychiatry*, 161, 1334-1349.

- Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Chen, Y., Ertugrul, A., et al. (2008). A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. *Journal of Clinical Psychiatry*, 69, 274-285.
- Monash Institute of Health Services Research (2006). *Evidence-Based Answers to Clinical Questions for Busy Clinicians*. The Centre for Clinical Effectiveness, Melbourne, Australia.
- National Advisory Mental Health Council Workgroup on Child and Adolescent Mental Health Intervention Development and Deployment. (2001). *Blueprint for change: Research on child and adolescent mental health*. Rockville, MD: National Institute of Mental Health. Available from <http://www.nimh.nih.gov>
- New Freedom Commission on Mental Health. (2003). *Achieving the promise: Transforming mental health care in America. Final Report*. (DHHS Publication. No. SMA-03-3832). Rockville, MD: Author.
- Ng, C. H., Chong, S., Lambert, T., Fan, A., Hackett, L., Mahendran, R., et al., (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. *International Clinical Psychopharmacology*, 20(3) 163-168.
- Parks, J. J. (2007). Implementing practice guidelines: Lessons from public mental health settings. *Journal of Clinical Psychiatry*, 68(Suppl 4), 45-48.
- Peters, T. J., & Waterman, R. H. (1982). *In search of excellence*. New York: Harper & Row.
- Rush, A. J., Jr., First, M. B., & Blacker, D. (Eds.). (2008). *Handbook of Psychiatric Measures* (2nd ed.). Arlington, VA: American Psychiatric Publishing, Inc.
- Sackett, D. L., Rosenberg, W. M. C., Gray, J. A. M., Haynes, A. B., & Richardson, W. S. (1996). Evidence based medicine: What it is and what it isn't. *British Medical Journal*, 312, 71-72.
- Sajatovic, M., & Ramirez, L. F. (2003). *Rating Scales in Mental Health* (2nd ed.). Hudson, Ohio: Lexi-Comp, Inc.
- Sernyak, M. J., Dausey, D., Desai, R., & Rosenheck, R. (2003). Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. *Psychiatric Services*, 54, 246-248.
- Simon, G. E., VonKorff, M., Rutter, C., & Wagner, E. (2000). Randomised trial of monitoring, feedback, and management of care by telephone to improved treatment of depression in primary care. *British Medical Journal*, 320, 550-554.
- Stahl, S. M., & Grady, M. M. (2004). A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation. *Current Medicinal Chemistry*, 11, 313-327.
- Taylor, A. C., Bond, G. R., Tsai, J., Howard, P. B., El-Mallakh, P., Finnerty, M., et al. (2009). Scales to evaluate quality of medication management: Development and psychometric properties. *Administration and Policy in Mental Health and Mental Health Services Research*. Published online February 27, 2009. DOI 10.1007/s10488-009-0209-z
- Teague, G. R., Drake, R. E., & Ackerson, T. (1995). Evaluating use of continuous treatment teams for persons with mental illness and substance abuse. *Psychiatric Services*, 46, 689-695.

- Toprac, M. G., Dennehy, E. B., Carmody, T. J., Crismon, M. L., Miller, A. L., Trivedi, M., et al. (2006). Implementation of the Texas Medication Algorithm Project patient and family education program. *Journal of Clinical Psychiatry*, *67*, 1362-1372.
- U.S. Department of Health and Human Services. (1999). *Mental health: A report of the Surgeon General*. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, and National Institutes of Health, National Institute of Mental Health.
- U.S. Department of Health and Human Services. (2001). *Mental health: Culture, race, and ethnicity—A supplement to Mental health: A report of the Surgeon General*. Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services.
- Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J. P., Citrome, L., McEvoy, J. P., et al. (2002). Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. *American Journal of Psychiatry*, *159*, 255–262; erratum, *159*, 2132.
- Weiden, P. J. (2007). Discontinuing and switching antipsychotic medications: Understanding the CATIE schizophrenia trial. *Journal of Clinical Psychiatry*, *68*(Suppl 1), 12-19.
- Weinmann, S., Koesters, M., & Becker, T. (2007). Effects of implementation of psychiatric guidelines on provider performance and patient outcome: Systematic review. *Acta Psychiatrica Scandinavica*, *115*, 420-433.
- Wells, K. B., Sherbourne, C., Schoenbaum, M., Duan, N., Meredith, L., Unutzer, J., et al. (2000). Impact of disseminating quality improvement programs for depression in managed primary care: A randomized controlled trial. *Journal of the American Medical Association*, *283*, 212-220.
- Worrall, G., Angel, J., Chaulk, P., Clarke, C., & Robbins, M. (1999). Effectiveness of an educational strategy to improve family physicians' detection and management of depression: A randomized controlled trial. *Canadian Medical Association Journal*, *161*, 37-40.
- Young, A. S., Sullivan, G., Burnam, M. A., & Brook, R. H. (1998). Measuring the quality of outpatient treatment for schizophrenia. *Archives of General Psychiatry*, *55*, 611-617.
- Young, G. J., Mohr, D. C., Meterko, M., Seibert, M. N., & McGlynn, G. (2006). Psychiatrists' self-reported adherence to evidence-based prescribing practices in the treatment of schizophrenia. *Psychiatric Services*, *57*, 130-132.

The Evidence

Acknowledgments

The materials included in the MedTEAM KIT were developed through the University of Texas at San Antonio. In partnership with many other collaborators, including clinicians, researchers, consumers, family members, and administrators, and operating under the direction of the Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, these materials were evaluated and revised.

We wish to acknowledge the many people who contributed to all aspects of this project. In particular, we wish to acknowledge the contributors and consultants on the next few pages.

SAMHSA Center for Mental Health Services, Oversight Committee

Michael English (deceased)

Division of Service and Systems Improvement
Rockville, Maryland

Neal B. Brown

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Sandra Black

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Crystal R. Blyler

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Pamela Fischer

Homeless Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Sushmita Shoma Ghose

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Patricia Gratton

Division of Service and Systems Improvement
Rockville, Maryland

Betsy McDonel Herr

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Larry D. Rickards

Homeless Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Ken Thompson

SAMHSA Center for Mental Health Services
Rockville, Maryland

Co-leaders

Tom Mellman

Dartmouth Medical School
Hanover, New Hampshire

Alexander Miller

University of Texas Health Science Center
at San Antonio
San Antonio, Texas

Troy Moore

University of Texas at San Antonio
San Antonio, Texas

Contributors

Neal Adams

California Institute of Mental Health
Soquel, California

Charity Appell

Ascutney, Vermont

Robert Arizpe

San Antonio State Hospital
San Antonio, Texas

Kate Bell

Humboldt County Department of Mental Health
Humboldt, California

Crystal R. Blyler

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Gary Bond

Indiana University, Purdue University
at Indianapolis
Indianapolis, Indiana

Neal Brown

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Barbara Burns

Duke University School of Medicine
Durham, North Carolina

Michael J. Cohen

National Alliance on Mental Illness (NAMI)
Concord, New Hampshire

Catherine Craig

University of Texas Health Science Center
at San Antonio
San Antonio, Texas

Lynn Crismon

University of Texas College of Pharmacy
San Antonio, Texas

Albana Dassori

University of Texas Health Science Center
at San Antonio
San Antonio, Texas

Robert Drake

Dartmouth Psychiatric Research Center
Concord, New Hampshire

Paul Eisenhauer

San Antonio, Texas

Susan Essock

The Mount Sinai School of Medicine
New York, New York

Anita Everett

SAMHSA
Rockville, Maryland

Molly Finnerty

New York State Office of Mental Health
New York, New York

Vijay Ganju

National Association of State Mental Health
Program Directors Research Institute
Alexandria, Virginia

Sushmita Shoma Ghose

Community Support Programs Branch
Division of Service and Systems Improvement
Rockville, Maryland

Cindy Hopkins

Texas Department of Mental Health and Mental
Retardation
San Antonio, Texas

Howard H. Goldman

University of Maryland School of Medicine
Baltimore, Maryland

Paul G. Gorman

Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Pat Howard

University of Kentucky
Lexington, Kentucky

Karin Kalk

California Institute of Mental Health
Ladera Ranch, California

H. Stephen Leff

The Evaluation Center at the Human Services
Research Institute
Cambridge, Massachusetts

Natalie Maples

University of Texas at San Antonio
San Antonio, Texas

Steven Marder

University of California at Los Angeles
Los Angeles, CA

Noel Mazade

National Association of State Mental Health
Program Directors Research Institute
Alexandria, Virginia

Carolee Moore

Center for Health Care Services
San Antonio, Texas

Mona Neaderhiser

University of Texas Health Science Center
at San Antonio
San Antonio, Texas

Joseph Parks

Missouri Department of Mental Health
Jefferson City, Missouri

Frank Perez

San Antonio, Texas

Ernest Quimby

Howard University
Washington, D.C.

Steven Shon

Texas Department of Mental Health and
Mental Retardation
Austin, Texas

Gus Sicard

Center for Healthcare Services
San Antonio, Texas

Steven Steury

Department of Mental Health
Washington, D.C.

Patricia Suppes

Stanford University School of Medicine
Stanford, Connecticut

Ken Thompson

SAMHSA Center for Mental Health Services
Rockville, Maryland

Marcia Toprac

Texas Department of Mental Health
and Mental Retardation
San Antonio, Texas

William Torrey

Dartmouth Medical School
Hanover, New Hampshire

Laura Van Tosh

Olympia, Washington

Madhukar Trivedi

University of Texas at San Antonio
San Antonio, Texas

Dawn Velligan

University of Texas at San Antonio
San Antonio, Texas

Ellen Weissman

The Mount Sinai School of Medicine
New York, New York

Consultants to the National Implementing Evidence-Based Practices Project**Dan Adams**

St. Johnsbury, Vermont

Diane C. Alden

New York State Office of Mental Health
New York, New York

Lindy Fox Amadio

Dartmouth Psychiatric Research Center
Concord, New Hampshire

Diane Asher

The University of Kansas
Lawrence, Kansas

Stephen R. Baker

University of Maryland School of Medicine
Baltimore, Maryland

Stephen T. Baron

Department of Mental Health
Washington, D.C.

Deborah R. Becker

Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Nancy L. Bolton

Cambridge, Massachusetts

Patrick E. Boyle

Case Western Reserve University
Cleveland, Ohio

Mike Brady

Adult and Child Mental Health Center
Indianapolis, Indiana

Ken Braiterman

National Alliance on Mental Illness (NAMI)
Concord, New Hampshire

Janice Braithwaite

Snow Hill, Maryland

Michael Brody

Southwest Connecticut Mental Health Center
Bridgeport, Connecticut

Mary Brunette

Dartmouth Psychiatric Research Center
Concord, New Hampshire

Sharon Bryson
Ashland, Oregon

Barbara J. Burns
Duke University School of Medicine
Durham, North Carolina

Jennifer Callaghan
The University of Kansas
School of Social Welfare
Lawrence, Kansas

Kikuko Campbell
Indiana University–Purdue University
Indianapolis, Indiana

Linda Carlson
University of Kansas
Lawrence, Kansas

Diana Chambers
Department of Health Services
Burlington, Vermont

Alice Claggett
University of Toledo College of Medicine
Toledo, Ohio

Marilyn Cloud
Department of Health and Human Services
Concord, New Hampshire

Melinda Coffman
The University of Kansas
Lawrence, Kansas

Jon Collins
Office of Mental Health and Addiction Services
Salem, Oregon

Laurie Coots
Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Judy Cox
New York State Office of Mental Health
New York, New York

Harry Cunningham
Dartmouth Psychiatric Research Center
Concord, New Hampshire

Gene Deegan
University of Kansas
Lawrence, Kansas

Natalie D. L.ca
Indiana University–Purdue University
Indianapolis, Indiana

Robert E. Drake
Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Molly Finnerty
New York State Office of Mental Health
New York, New York

Laura Flint
Dartmouth Evidence Based Practices Center
Burlington, Vermont

Vijay Ganju
National Association of State Mental Health
Program Directors Research Institute
Alexandria, Virginia

Susan Gingerich
Narberth, Pennsylvania

Phillip Glasgow
Wichita, Kansas

Howard H. Goldman
University of Maryland School of Medicine
Baltimore, Maryland

Paul G. Gorman

Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Gretchen Grappone

Concord, New Hampshire

Eileen B. Hansen

University of Maryland School of Medicine
University of Maryland, Baltimore

Kathy Hardy

Stafford, Vermont

Joyce Hedstrom

Courtland, Kansas

Lon Herman

Department of Mental Health
Columbus, Ohio

Lia Hicks

Adult and Child Mental Health Center
Indianapolis, Indiana

Debra Hrouda

Case Western Reserve University
Cleveland, Ohio

Bruce Jensen

Indiana University–Purdue University
Indianapolis, Indiana

Clark Johnson

Salem, New Hampshire

Amanda M. Jones

Indiana University–Purdue University
Indianapolis, Indiana

Joyce Jorgensen

Department of Health and Human Services
Concord, New Hampshire

Hea-Won Kim

Indiana University–Purdue University
Indianapolis, Indiana

David A. Kime

Transcendent Visions and Crazy Nation Zines
Fairless Hills, Pennsylvania

Dale Klatzker

The Providence Center
Providence, Rhode Island

Kristine Knoll

Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Bill Krenek

Department of Mental Health
Columbus, Ohio

Rick Kruszynski

Case Western Reserve University
Cleveland, Ohio

H. Stephen Leff

The Evaluation Center at the Human Services
Research Institute
Cambridge, Massachusetts

Treva E. Lichti

National Alliance on Mental Illness (NAMI)
Wichita, Kansas

Wilma J. Lutz

Ohio Department of Mental Health
Columbus, Ohio

Anthony D. Mancini

New York State Office of Mental Health
New York, New York

Paul Margolies

Hudson River Psychiatric Center
Poughkeepsie, New York



Tina Marshall

University of Maryland School of Medicine
Baltimore, Maryland

Ann McBride (deceased)

Oklahoma City, Oklahoma

William R. McFarlane

Maine Medical Center
Portland, Maine

Mike McKasson

Adult and Child Mental Health Center
Indianapolis, Indiana

Alan C. McNabb

Ascutney, Vermont

Meka McNeal

University of Maryland School of Medicine
Baltimore, Maryland

Ken Minkoff

ZiaLogic
Albuquerque, New Mexico

Michael W. Moore

Office of Mental Health and Addiction Services
Salem, Oregon

Roger Morin

The Center for Health Care Services
San Antonio, Texas

Lorna Moser

Indiana University–Purdue University
Indianapolis, Indiana

Kim T. Mueser

Dartmouth Psychiatric Research Center
Concord, New Hampshire

Britt J. Myrhol

New York State Office of Mental Health
New York, New York

Bill Naughton

Southeastern Mental Health Authority
Norwich, Connecticut

Nick Nichols

Department of Health
Burlington, Vermont

Bernard F. Norman

Northeast Kingdom Human Services
Newport, Vermont

Linda O'Malia

Oregon Health and Science University
Portland, Oregon

Ruth O. Ralph

University of Southern Maine
Portland, Maine

Angela L. Rollins

Indian University–Purdue University
Indianapolis, Indiana

Tony Salerno

New York State Office of Mental Health
New York, New York

Diana C. Seybolt

University of Maryland School of Medicine
Baltimore, Maryland

Patricia W. Singer

Santa Fe, New Mexico

Mary Kay Smith

University of Toledo
Toledo, Ohio

Diane Sterenbuch
Bethesda, Maryland

Bette Stewart
University of Maryland School of Medicine
Baltimore, Maryland

Steve Stone
Mental Health and Recovery Board
Ashland, Ohio

Maureen Sullivan
Department of Health and Human Services
Concord, New Hampshire

Beth Tanzman
Vermont Department of Health
Burlington, Vermont

Greg Teague
University of Southern Florida
Tampa, Florida

Boyd J. Tracy
Dartmouth Psychiatric Research Center
Lebanon, New Hampshire

Laura Van Tosh
Olympia, Washington

Joseph A. Vero
National Alliance on Mental Illness (NAMI)
Aurora, Ohio

Barbara L. Wieder
Case Western Reserve University
Cleveland, Ohio

Mary Woods
Westbridge Community Services
Manchester, New Hampshire



Special thanks

Special thanks to the Robert Wood Johnson Foundation for its generous contribution.

Production, editorial, and graphics support

Carolyn Boccella Bagin

Center for Clear Communication, Inc.
Rockville, Maryland

Jason Davis

Westat
Rockville, Maryland

Sushmita Shoma Ghose

Westat
Rockville, Maryland

Julien P. Hofberg

Westat
Rockville, Maryland

Chandria Jones

Westat
Rockville, Maryland

Glynis Jones

Westat
Rockville, Maryland

Tina Marshall

Westat
Rockville, Maryland

Mary Anne Myers

Westat
Rockville, Maryland

